Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NTRK1 fusion
i
Other names:
NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4914
Related biomarkers:
Expression
Mutation
Fusion
Others
‹
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
repotrectinib
Sensitive: A1 - Approval
repotrectinib
Sensitive
:
A1
repotrectinib
Sensitive: A1 - Approval
repotrectinib
Sensitive
:
A1
NTRK1 fusion
Sarcoma
NTRK1 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
NTRK1 fusion
Solid Tumor
NTRK1 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
larotrectinib
Sensitive: A1 - Approval
larotrectinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Adenocarcinoma
NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Breast Cancer
NTRK1 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Gastrointestinal Stromal Tumor
NTRK1 fusion
Gastrointestinal Stromal Tumor
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Sarcoma
NTRK1 fusion
Sarcoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Peritoneal Cancer
NTRK1 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Peritoneal Cancer
NTRK1 fusion
Peritoneal Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Fallopian Tube Cancer
NTRK1 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Fallopian Tube Cancer
NTRK1 fusion
Fallopian Tube Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
NTRK1 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
NTRK1 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Cancer
NTRK1 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Cancer
NTRK1 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Gastrointestinal Stromal Tumor
NTRK1 fusion
Gastrointestinal Stromal Tumor
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Non Small Cell Lung Cancer
NTRK1 fusion
Non Small Cell Lung Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Soft Tissue Sarcoma
NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Adenocarcinoma
NTRK1 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Esophageal Cancer
NTRK1 fusion
Esophageal Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Esophageal Cancer
NTRK1 fusion
Esophageal Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Cervical Cancer
NTRK1 fusion
Cervical Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login